Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Polysleep and Matelas Bonheur announce a new partnership 15-03-2023, 20:39

Future Health Index 2024 global report: Healthcare leaders turn to AI to address critical gaps in patient care 18-06-2024, 16:00